• Conference
  • Earn CE
  • Free Samples
  • Magazine
  • Subscribe
  • Videos
    • Recent Quotes
    My Watchlist
    Indicators
    Dental Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Ligand Pharm (NQ: LGND )

    106.33 +1.13 (+1.07%)
    Streaming Delayed Price Updated: 4:00 PM EDT, Aug 27, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 160,270
    Open 104.58
    Bid (Size) 106.09 (2)
    Ask (Size) 106.35 (8)
    Prev. Close 105.20
    Today's Range 104.50 - 106.48
    52wk Range 49.24 - 112.12
    Shares Outstanding 16,676,532
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    Ligand to Present at H.C. Wainwright 26th Annual Global Investment Conference
    From Ligand Pharmaceuticals Incorporated
    Via Business Wire
    Looking Into Ligand Pharmaceuticals's Recent Short Interest
    Via Benzinga

    Performance

    YTD
    +47.05%
    +47.05%
    1 Month
    -2.23%
    -2.23%
    3 Month
    +23.67%
    +23.67%
    6 Month
    +42.88%
    +42.88%
    1 Year
    +63.69%
    +63.69%

    More News

    Read More
    Stock Market Rally Begins After Global Rout; Palantir, Eli Lilly, Fortinet Jump: Weekly Review
    Via Investor's Business Daily
    LGND Stock Earnings: Ligand Pharmaceuticals Beats EPS, Beats Revenue for Q2 2024
    Via InvestorPlace
    Assessing Ligand Pharmaceuticals: Insights From 6 Financial Analysts
    Via Benzinga
    What 4 Analyst Ratings Have To Say About Ligand Pharmaceuticals
    Via Benzinga
    Halozyme And Ligand — Two Leading Biotechs — Smash Quarterly Forecasts
    Via Investor's Business Daily
    Ligand Reports Second Quarter 2024 Financial Results
    From Ligand Pharmaceuticals Incorporated
    Via Business Wire
    Ligand to Report Second Quarter 2024 Financial Results on August 6, 2024
    From Ligand Pharmaceuticals Incorporated
    Via Business Wire
    5 Best Short-Term Stocks to Consider Investing In
    Via MarketBeat
    Ligand to Acquire APEIRON Biologics AG for $100 Million
    From Ligand Pharmaceuticals Incorporated
    Via Business Wire
    Lifecore Biomedical Announces Cooperation Agreement with 22NW
    From Lifecore Biomedical, Inc.
    Via GlobeNewswire
    Ligand Partner Verona Pharma Announces FDA Approval of Ohtuvayre™ (ensifentrine), First Inhaled Novel Mechanism for Maintenance Treatment of COPD in More Than 20 Years
    From Ligand Pharmaceuticals Incorporated
    Via Business Wire
    Ligand Collaborator Merck Receives FDA Approval for CAPVAXIVE™ (Pneumococcal 21-valent Conjugate Vaccine) for Adults
    From Ligand Pharmaceuticals Incorporated
    Via Business Wire
    Ligand to Participate in Upcoming Investor Conferences
    From Ligand Pharmaceuticals Incorporated
    Via Business Wire
    3 Magnificent Growth Stocks to Buy Hand Over Fist
    Via The Motley Fool
    Topics Economy
    Exposures Interest Rates
    3 Must-Buy Biotech Stocks Before the Summer Rally Kicks Off
    Via InvestorPlace
    LGND Stock Earnings: Ligand Pharmaceuticals Beats EPS, Beats Revenue for Q1 2024
    Via InvestorPlace
    Ligand Reports First Quarter 2024 Financial Results
    From Ligand Pharmaceuticals Incorporated
    Via Business Wire
    Ligand and Agenus Enter Into $100 Million Royalty Financing Agreement
    From Ligand Pharmaceuticals Incorporated
    Via Business Wire
    Don't Overlook These Top Medical Stocks As Q1 Earnings Approach
    Via Talk Markets
    Ligand to Report First Quarter 2024 Financial Results on May 7, 2024
    From Ligand Pharmaceuticals Incorporated
    Via Business Wire
    7 Small-Cap Stocks for the Thinking Speculator
    Via InvestorPlace
    Ligand Pharmaceuticals Announces New Topiramate Injection Data Presented at 9th London-Innsbruck Colloquium on Status Epilepticus and Acute Seizures Conference
    From Ligand Pharmaceuticals Incorporated
    Via Business Wire
    Ligand Pharmaceuticals Announces Launch of Pelthos Therapeutics to Accelerate Commercialization of ZELSUVMI™
    From Ligand Pharmaceuticals Incorporated
    Via Business Wire
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.